HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing

This article was originally published in The Rose Sheet

Executive Summary

Merck agrees to pay a maximum of $10 million to consumers to settle class-action litigation. Firm’s compliance with sunscreen labeling and claims requirements that will become law in December under an FDA final rule satisfies plaintiffs, who took issue with past Coppertone claims that allegedly overstated products’ sun-protective benefits. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.

You may also be interested in...



Merck Faces Consumer Suit Over Coppertone UV Claims

A New Jersey-based suit seeking class action certification alleges Merck has misrepresented the UV-protective benefits of its Coppertone sunscreen products, subjecting consumers to potential risks.

In Brief

FDA pushes back deadlines for compliance with its final rule for sunscreen labeling and effectiveness testing, giving manufacturers an additional six months for products with annual sales of at least $25,000. More news in brief.

Tests Show CBD Levels In Some Supplements Don't Match Labeling

Seven of 10 CBD-containing supplement products tested in a lab did not contain the levels of CBD advertised on the label, says hemp, CBD and natural health product information publisher Remedy Reviews. Most products also were found to contain heavy metals.

UsernamePublicRestriction

Register

RS018299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel